Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations

Breast Cancer Research and Treatment

Volumn 147, Issue 2, 2014, Pages 227-235

  Maugeri Saccà, Marcello ^a   Barba, Maddalena ^a   Vici, Patrizia ^a   Pizzuti, Laura ^a   Sergi, Domenico ^a   De Maria, Ruggero ^a   Di Lauro, Luigi ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Aromatase inhibitors; GnRH analogue; Hormone receptor pathways; Male breast cancer

Indexed keywords

ANASTROZOLE; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; LEUPRORELIN; TAMOXIFEN; ANTINEOPLASTIC AGENT;

AGING; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; DRUG TOLERABILITY; DRUG USE; HORMONAL THERAPY; HUMAN; MALE BREAST CANCER; MOLECULAR BIOLOGY; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; BREAST NEOPLASMS, MALE; DRUG EFFECTS; ENDOCRINE SYSTEM; HORMONE SUBSTITUTION; MALE; PATHOPHYSIOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS, MALE; ENDOCRINE SYSTEM; HORMONE REPLACEMENT THERAPY; HUMANS; MALE;

EID: 84922073411     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3087-3     Document Type: Review

References (55)

1. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer 101:51–57
2. Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24:1434–1443
3. Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, Casagrande JT, et al (2014) Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst 106:doi: 10.1093/jnci/djt465
4. Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28:232–239
5. Cardoso F, Bischoff J, Brain E, Zotano ÁG, Lück HJ, Tjan-Heijnen VC et al (2013) A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 39:457–465
6. Johansson I, Nilsson C, Berglund P, Lauss M, Ringnér M, Olsson H et al (2012) Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies Nacetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 14:R31
7. Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S et al (2011) Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 127:601–610
8. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I (2002) Estradiol in elderly men. Aging Male 5:98–102
9. Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW et al (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465–470
10. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874
11. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27:4515–4521
12. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
13. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352
14. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333–339
15. Rudlowski C, Schulten HJ, Golas MM, Sander B, Barwing R, Palandt JE et al (2006) Comparative genomic hybridization analysis on male breast cancer. Int J Cancer 118:2455–2460
16. Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MC, de Bruin PC, Oudejans JJ et al (2012) Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res 14:R101
17. Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MC, de Bruin PC, Oudejans JJ et al (2012) Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 135:49–58
18. Johansson I, Nilsson C, Berglund P, Strand C, Jönsson G, Staaf J et al (2011) High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat 129:747–760
19. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570
20. Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, Dent J et al (2012) A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 133:949–958
21. Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG et al (2009) MicroRNA expression profiling of male breast cancer. Breast Cancer Res 11:R58
22. Johansson I, Ringnér M, Hedenfalk I (2013) The landscape of candidate driver genes differs between male and female breast cancer. PLoS ONE 8:e78299
23. Patani N, Martin LA (2014) Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol Cell Endocrinol 382:683–694
24. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45:1446–1451
25. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M et al (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439–1445
26. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116–1130
27. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R et al (2013) D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 73:6856–6864
28. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529
29. Turner KJ, Morley M, Atanassova N, Swanston ID, Sharpe RM (2000) Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 164:225–238
30. Mauras N, O’Brien KO, Klein KO, Hayes V (2000) Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85:2370–2377
31. T’Sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman JM (2005) Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab 90:5717–5722
32. Bighin C, Lunardi G, Del Mastro L, Marroni P, Taveggia P, Levaggi A et al (2010) Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors. Oncologist 15:1270–1272
33. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C (2004) Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 89:1174–1180
34. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ (2009) Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol 70:116–123
35. Lopez M, Di Lauro L, Lazzaro B, Papaldo P (1985) Hormonal treatment of disseminated male breast cancer. Oncology 42:345–349
36. Lopez M (1985) Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer 55:2334–2336
37. Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S (1993) Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer 72:502–505
38. Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D et al (2007) Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 105:169–175
39. Takagi K, Moriya T, Kurosumi M, Oka K, Miki Y, Ebata A et al (2013) Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma. Horm Cancer 4:1–11
40. White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V (2011) Male breast carcinoma: increased awareness needed. Breast Cancer Res 13:219
41. Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI (1994) Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 74:74–77
42. Visram H, Kanji F, Dent SF (2010) Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 17:17–21
43. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH (2012) Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol 23:1471–1474
44. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN (2002) Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25:235–237
45. Zabolotny BP, Zalai CV, Meterissian SH (2005) Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90:26–30
46. Arriola E, Hui E, Dowsett M, Smith IE (2007) Aromatase inhibitors and male breast cancer. Clin Transl Oncol 9:192–194
47. Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A (2010) Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 21:1243–1245
48. Giordano SH, Hortobagyi GN (2006) Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24:e42–e43
49. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P et al (2013) Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108:2259–2263
50. Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D et al (2013) Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat 141:119–123
51. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114–2122
52. Lopez M, Di Lauro L, Papaldo P, Lazzaro B (1985) Chemotherapy in metastatic male breast cancer. Oncology 42:205–209
53. Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G et al (2013) Fulvestrant and male breast cancer: a case series. Ann Oncol 24:265–266
54. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005
55. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197